Literature DB >> 1180697

Vaccinia virus variants as presumable cause of vaccinial complications.

W Ehrengut, D E Sarateanu, U Alswede, A Habib, G Tetzlaff.   

Abstract

Two vaccinia viruses isolated from patients with vaccinial complications (vaccinial ulcer, postvaccinial seizures) showed qualitative differences from the original parental strain. After intradermal injection of the viruses into the rabbit marked necroses developed, which the original strains did not produce. While the parental virus did not grow on the chorioallantoic membrane at 41 degrees C after 2 days incubation, the vaccinia variant produced typical lesions at that temperature. Also the yield of infectious virus on various cell systems was 1--2.5 logs higher for the virus than for the original vaccine strain. With the plaque technique differences were seen in the appearance and size of plaques between the variant and the parental vaccinia strain. These results indicate that virus of an increased pathogenicity could be isolated from the patients and this might be causally connected with the postvaccinial complications from which they were suffering.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1180697     DOI: 10.1007/bf01317965

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  15 in total

1.  COMPARATIVE STUDY OF GENETIC MARKERS OF SOME POX VIRUS STRAINS.

Authors:  Y Z GHENDON; V I CHERNOS
Journal:  Acta Virol       Date:  1964-07       Impact factor: 1.162

2.  THE USE OF CEILING TEMPERATURE AND REACTIVATION IN THE ISOLATION OF POX VIRUS HYBRIDS.

Authors:  K R DUMBELL; H S BEDSON
Journal:  J Hyg (Lond)       Date:  1964-06

3.  The effect of temperature on the growth of pox viruses in the chick embryo.

Authors:  H S BEDSON; K R DUMBELL
Journal:  J Hyg (Lond)       Date:  1961-12

4.  A study of the immunogenicity of smallpox vaccines.

Authors:  V D SOLOVIEV; Y N MASTYUKOVA
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408

5.  [Behaviour of vaccinia virus in central nervous injury caused by vaccine. I. Virological studies at the inoculation site, in the regional lymph nodes and in the blood].

Authors:  R SIEGERT
Journal:  Dtsch Med Wochenschr       Date:  1957-11-29       Impact factor: 0.628

6.  The biological characters of several strains of vaccinia, cowpox and rabbitpox viruses.

Authors:  F FENNER
Journal:  Virology       Date:  1958-06       Impact factor: 3.616

7.  Variability in the characteristics of pocks produced on the chick chorioallantois by white pock mutants of cowpox and other poxviruses.

Authors:  D Baxby
Journal:  J Hyg (Lond)       Date:  1969-12

8.  Relation of infectious and lethal activities of three strains of Vaccinia virus to the incubation temperature.

Authors:  D Slonim; M Hulenová
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1972

9.  [Intensification of the virulence of vaccinia virus by repeated passages at supra-optimal temperature].

Authors:  A Kirn; J Braunwald; A Dammron
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1965-06-09

10.  [Differences in the quality of vaccinia viruses with normal and abnormal post-vaccination course (with neurological complications) (author's transl)].

Authors:  W Ehrengut; D E Sarateanu
Journal:  Dtsch Med Wochenschr       Date:  1975-07-04       Impact factor: 0.628

View more
  2 in total

1.  Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys.

Authors:  M Morita; Y Aoyama; M Arita; H Amona; H Yoshizawa; S Hashizume; T Komatsu; I Tagaya
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

Review 2.  ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

Authors:  Thomas P Monath; Joseph R Caldwell; Wolfgang Mundt; Joan Fusco; Casey S Johnson; Mark Buller; Jian Liu; Bridget Gardner; Greg Downing; Paul S Blum; Tracy Kemp; Richard Nichols; Richard Weltzin
Journal:  Int J Infect Dis       Date:  2004-10       Impact factor: 3.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.